




PHARMACEUTICAL 2022

2seventy bio Inc.
Rank 306 of 466





PHARMACEUTICAL 2022

2seventy bio Inc.
Rank 306 of 466



The relative strengths and weaknesses of 2seventy bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of 2seventy bio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 115% points. The greatest weakness of 2seventy bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 22% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	291,564
Cost of Goods Sold	2,517
Intangible Assets	21,948
Liabilities, Current	98,388
Liabilities, Non-Current	300,330
Other Assets	411,250
Other Compr. Net Income	-712
Other Expenses	10,510
Other Liabilities	1,135
Other Net Income	21,735
Other Revenues	54,522
Property and Equipment	34,913
Research and Development	261,937
Selling, General and Administrative Expense	93,506

Output Variable	Value in 1000 USD
Assets	759,675
Liabilities	399,853
Expenses	368,470
Revenues	54,522
Stockholders Equity	359,822
Net Income	-292,213
Comprehensive Net Income	-292,569
Economic Capital Ratio	56%